Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.54 |
| ▸ | AGXT | P21549 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8988644 | 0.81 | IDO1 (0.60) | IDO1CYP3A4CA1CA2 | |
| SCHEMBL10102079 | 0.81 | IDO1 (0.58) | IDO1AGXTCYP3A4 | |
| SCHEMBL13318420 | 0.80 | TAAR1 (0.42) | CYP3A4 | |
| Hydrochloric Acid SCHEMBL9567644 | 0.79 | IDO1 (0.61) | IDO1AGXTCYP3A4CA1CA2 | |
| Hydrochloric Acid SCHEMBL662808 | 0.79 | IDO1 (0.59) | IDO1AGXTCYP3A4 | |
| SCHEMBL14802026 | 0.77 | TAAR1 (0.48) | CYP3A4 | |
| SCHEMBL30081509 | 0.77 | TAAR1 (0.48) | CYP3A4 | |
| SCHEMBL1338001 | 0.76 | KDM4E (0.52) | CYP3A4 | |
| SCHEMBL30058625 | 0.76 | CA1 (0.61) | CYP3A4CA1CA2 | |
| SCHEMBL545298 | 0.76 | CA1 (0.61) | CYP3A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PARK7, SNCA, RHOT2 | IDO1 2040/4885AGXT 1004/4885CYP3A4 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.